Thromboembolic Events Burden in Patients With Solid Tumors and Their Predisposing Factors: A Cross-Sectional Study

Shouki Bazarbashi (✉ bazarbashi@gmail.com)
King Faisal Specialist Hospital and Research Center  https://orcid.org/0000-0002-8913-8158

Turkiah Alkhaldi
King Fahad Medical City

Maryam Melaibari
King Abdulaziz University

Sara Almuhisen
King Fahad Medical City

Samar Al-Harbi
King Faisal Specialist Hospital and Research Center

Jihad Aljumaa
Alfaisal University College of Medicine

Abdelmoneim Eldali
King Faisal Specialist Hospital and Research Center

Fatma Maraiki
King Faisal Specialist Hospital and Research Center

Mohamed Aseafan
King Faisal Specialist Hospital and Research Center

Tarek Owaidah
King Faisal Specialist Hospital and Research Center

Hazzaa Alzahrani
King Faisal Specialist Hospital and Research Center

Research Article

Keywords: Thromboembolism, cancer, Khorana score, anti-neoplastic therapy, central venous catheter

DOI: https://doi.org/10.21203/rs.3.rs-486821/v1

License: ☕️ 🍀 This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background: The relationship between cancers and thromboembolic events is well established. In our study we aim to determine the burden of thromboembolic events in patients with solid tumors and identify the risk factors related to their development.

Methods: Data on patients with solid tumors and thromboembolism between January 2013 and September 2014 were collected and analyzed.

Results: During the studied period 174 patients were identified, 172 (98.9%) of which had venous thrombus embolism. 137 (79%) were diagnosed with deep vein thromboses and 67 (38.5%) with pulmonary embolisms. 84 (48.3%) were symptomatic and 90 (51.7) were incidental at diagnosis. The most common risk factors were female sex, high Body mass index, metastatic stage, colorectal and breast primaries, and anti-neoplastic therapy.

Conclusion: Our study confirmed the high burden of thromboembolic events in cancer patients and the relevant risk factors associated with its development.

Background

The relationship between cancers and thromboembolic events (TEEs), including venous thromboembolisms (VTEs) and arterial thromboembolisms (ATEs), is well-known and well-established (1–3). Evidence has shown that cancer patients have a higher risk of developing TEEs in comparison with non-cancer patients (3). This increased risk results in an overall incidence of 1 to 43% in various cancers (4). VTEs account for the majority (70–90%) of cases while ATEs account for only 10–30% (2). Many studies have suggested that the incidence of TEEs varies according to ethnic background. Some western studies have reported that African Americans and Caucasians have a higher incidence in comparison with Hispanics and Native Americans (5). On the other hand, most Asian studies have suggested a lower incidence of VTEs in Asian cancer patients as compared to western studies (6–9).

Along with typical TEE risk factors such as obesity, advanced age, and prolonged immobilization, cancer patients have additional risks that influence the development of TEEs. The type of malignancy, type of anti-neoplastic therapy, and presence of metastases have been considered major risk factors in cancer patients (10, 11). Many studies have shown that VTEs occur at a higher frequency in patients with cancers of the pancreas, ovaries, and kidneys (4, 12, 13). Certain anti-neoplastic medications also have a notably higher risk of causing TEEs. Moore et al. noted that in their study, 18.1% of patients who received cisplatin developed either VTEs or ATEs (13). Patients receiving chemotherapy regimens containing gemcitabine also were found to be at a higher risk of developing VTEs and ATEs than those receiving non-gemcitabine-containing regimens (14). Hormonal agents such as tamoxifen, newer anti-neoplastic agents such as anti-angiogenic agents, and anti-epidermal growth factor receptor antibodies have all been shown to increase the risk of VTEs and ATEs in cancer patients in several studies (15–18).
Additionally, patients with metastatic diseases were found to be at a higher risk for VTEs, the risk ranging from 1.4–21.5-fold, compared to patients with limited disease (5, 19).

Established guidelines recommend primary prophylaxis for all hospitalized cancer patients, including those with reduced mobility and central venous catheters (20). Routine pharmacologic thromboprophylaxis for outpatient cancer patients is still controversial and not widely recommended (21, 22). Several attempts have been made to establish a scoring system based on known risk factors to identify cancer patients at a higher risk for VTEs. The most popular are the Khorana Model, the Vienna modification of the Khorana Model, the PROTECHT scoring system, the CONKO score, and the most recently described but not validated COMPASS-CAT scoring system (21, 23–27). Whether thromboprophylaxis results in a significant reduction in VTEs among high-risk groups remains to be established.

The primary objective of this study was to determine the incidence of different types of TEEs in patients with solid tumors and established thromboembolism diagnoses at a single institution in the Middle East. In addition, the study identified the characteristics and risk factors related to thrombosis events.

**Methods**

**Study design**

This was a retrospective single-institution study conducted at a national referral center for cancer in Saudi Arabia. Patients with solid tumor diagnoses who had developed TEEs in either the inpatient or outpatient setting between January 2013 and September 2014 were eligible for inclusion.

**Data collection**

The medical records of the eligible patients were reviewed for the following information: patient-related factors, which include age, sex, body mass index, co-morbid conditions, and Eastern Cooperative Oncology Group (ECOG) performance status; cancer related factors, which include the primary tumor site and disease stage; treatment-related factors, including anti-neoplastic agents and radiotherapy in use at the time of the TEE; recent surgical procedures, and blood transfusions. Finally, TEE-related factors, including the types (venous versus arterial) were reviewed. Other information, such as diagnosis method, clinical presentation, previous TEE history, history of current VTE prophylaxis, hospitalization at the time of TEE, relationship to the central venous catheters, and finally, the Khorana Score.

The study was conducted in accordance with the ethical principles contained in the declaration of Helsinki (2000), Good Clinical Practice Guidelines and the policies and guidelines of the institution it was carried in. The study was approved by the institutional review board. In view of the retrospective nature of the study, a waiver of consent was obtained from the institutional review board. The identity of the
patients studied remained anonymous, since no identifying data or protected health information were recorded. All data were password secured to safeguard the confidentiality of the collected patient’s data.

Statistical analysis

The Statistical Package for Social Sciences software version 20 (SPSS: IBM Co., USA) was used to analyze the data. Continuous variables were described as mean ± standard deviation, categorical variables were described as numbers (percentages), and cross-tabulation was used to summarize the relationships between two categorical variables.

Results

A total of 312 medical records were reviewed, and 174 of them met the eligibility criteria. The most common thromboembolism (98.9%) was venous TEE, as seen in Table 1. The venous TEEs were most commonly presented as peripheral deep venous thrombosis (DVT) (50%), which combined upper and lower DVT, and pulmonary embolism (PE) (38.5%). Others were visceral veins thrombosis (17.2%), jugular thrombosis (8%), and renal vein thrombosis (3.4%). Nearly half of the patients were symptomatic, and the rest were diagnosed incidentally. The commonest diagnostic method was CT scan (69%). 31% of patients were admitted for management of their TEEs. Risk factors such as previous incidence of TEE at diagnosis and relation to central venous catheter were low (8.6% and 13.8%, respectively). 23% of patients were diagnosed with TEE during hospitalization. The majority of patients had either an intermediate or high Khorana Score (73%) with only 10.3% of them on a DVT prophylaxis treatment at the time of TEE diagnosis.
Table 1
Incidence, characteristics, and risk factors related to 174 TEE events.

| Item                                           | No (%)         |
|------------------------------------------------|----------------|
| **Type of TEE**a                              |                |
| Arterial                                       | 2 (1.1)        |
| Venous                                         | 172 (98.9)     |
| **PE**b                                        |                |
| DVTc                                           |                |
| Lower extremities DVT                          | 44 (25.3)      |
| Upper extremities DVT                          | 29 (16.7)      |
| Other venous thrombosis                       |                |
| Jugular                                        | 14 (8)         |
| Renal vein thrombosis                         | 6 (3.4)        |
| Visceral veins thrombosis                     | 30 (17.2)      |
| **Clinical presentation**                     |                |
| Symptomatic                                    | 84 (48.3)      |
| Incidental                                     | 90 (51.7)      |
| **Diagnostic method**                         |                |
| Computerized tomography                       | 120 (69)       |
| Ultrasonography                                | 52 (29.9)      |
| Computerized tomography angiography           | 2 (1.1)        |
| **History of TEEs**                           |                |
| Current hospitalization at TEE                 | 40 (23)        |
| Admission because of TEE                      | 54 (31)        |
| Relation to central venous catheter           | 24 (13.8)      |

a. TEEs; Thromboembolic events, b. PE; pulmonary embolism, c. DVT; deep vein thrombosis, d. VTE; venous thromboembolism
| Item                                           | No (%)  |
|------------------------------------------------|---------|
| Current VTE\(^d\) prophylaxis at diagnosis     | 18 (10.3) |
| Khorana Score                                  |         |
| Low                                            | 37 (21.3) |
| Intermediate                                   | 93 (53.5) |
| High                                           | 34 (19.5) |
| Not identified                                 | 10 (5.7)  |

a. TEEs; Thromboembolic events, b. PE; pulmonary embolism, c. DVT; deep vein thrombosis, d. VTE; venous thromboembolism

Baseline risk factors characteristic are shown in Table 2. The majority of patients were females (69%) and had ECOG performance status of 2 or higher (47.7%). The mean body mass index (BMI) was 28 kg/m\(^2\). Hypertension (27%) and diabetes mellitus (21.3%) were the most common associated co-morbidities. Colorectal cancer represented the largest group of cancer patients (19%), followed by breast cancer (18.4%) and lymphoma (10.9%); an almost similar incidence occurred among ovarian, stomach, ampullary, and lung cancers (~5–7%). Most of the TEE cases were found in patients with metastatic disease (71.8%). Of the 125 patients with metastatic disease 80 (64%) received anti-neoplastic therapy (targeted, hormonal, and/or chemotherapy), with a similar percentage for non-metastatic diseases. In all patient groups, 62% of patients were on chemotherapy within two months prior to their TEE diagnosis. Other treatment-related risk factors such as surgery, blood transfusion, and radiotherapy were low (<20%). The most common chemotherapy agents were capecitabine and oxaliplatin (>10%), which is in accordance with the most common cancer diagnosis colorectal cancer.
Table 2  
Baseline risk factors and characteristics of 174 TEE.

| Item                                   | No (%)          |
|----------------------------------------|-----------------|
| Age, median (range)                    | 50 ± 16.5       |
| Sex                                    |                 |
| Male                                   | 54 (31)         |
| Female                                 | 120 (69)        |
| BMI<sup>a</sup> (mean ± SD<sup>b</sup>) | 28 ± 6          |
| Co-morbidities                         |                 |
| Hypertension                           | 47 (27)         |
| Diabetes Mellitus                      | 37 (21.3)       |
| Lung Disease                           | 13 (7.5)        |
| Atrial fibrillation/flutter            | 5 (2.9)         |
| Heart Failure                          | 3 (1.7)         |
| Liver Disease                          | 2 (1.1)         |
| Others                                 | 4 (25.3)        |
| Performance status (ECOG<sup>c</sup>)  |                 |
| 0                                      | 10 (5.7)        |
| 1                                      | 53 (30.5)       |
| 2                                      | 40 (23)         |
| 3                                      | 35 (20.1)       |
| 4                                      | 8 (4.6)         |
| Unknown                                | 28 (16.1)       |
| Primary malignancy                     |                 |

<sup>a</sup> BMI; body mass index, <sup>b</sup> SD; standard deviation, <sup>c</sup> ECOG; Eastern Cooperative Oncology Group
| Item                | No (%) |
|---------------------|--------|
| Colorectal          | 33 (19)|
| Breast              | 32 (18.4)|
| Lymphoma            | 19 (10.9)|
| Ovary               | 13 (7.6)|
| Stomach             | 12 (6.9)|
| Ampulla of vater    | 12 (6.9)|
| Lung                | 11 (6.3)|
| Pancreas            | 8 (4.6)|
| Corpus uteri        | 5 (2.9)|
| Head and neck       | 3 (1.7)|
| Liver               | 2 (1.1)|
| Cervix uteri        | 2 (1.1)|
| Sarcoma             | 2 (1.1)|
| Esophagus           | 1 (0.6)|
| Others              | 19 (10.9)|

| Cancer stage        |        |
|---------------------|--------|
| Localized           | 22 (12.6)|
| Regional            | 27 (15.6)|
| Metastatic          | 125 (71.8)|

| Treatment received within 60 days |        |
|-----------------------------------|--------|
| Major surgery                     | 22 (12.6)|
| Blood transfusion                 | 31 (17.8)|
| Radiotherapy                      | 11 (6.3)|
| Targeted therapy                  | 27 (15.5)|
| Hormonal therapy                  | 8 (4.6)|

a. BMI; body mass index, b. SD; standard deviation, c. ECOG; Eastern Cooperative Oncology Group
| Item                 | No (%) |
|---------------------|--------|
| Chemotherapy        | 108 (62) |
| Capecitabine        | 28 (16.1) |
| Oxaliplatin         | 27 (15.5) |
| Cyclophosphamide    | 17 (9.8) |
| 5-Fluorouracil      | 16 (9.2) |
| Doxorubicin         | 15 (8.6) |
| Cisplatin           | 12 (6.9) |
| Carboplatin         | 11 (6.3) |
| Vincristine         | 10 (5.7) |
| Gemcitabine         | 7 (4) |
| 6-Mercaptopurine    | 2 (1.1) |
| Cytarabine          | 1 (0.6) |
| Others              | 34 (19.5) |
| Not on treatment    | 44 (25) |

Discussion

Our study represents an evaluation of all TEEs diagnosed in patients with solid tumors within a two-year period at a single institution. The study showed a majority of venous TEEs, with the most common being DVT (50%) and PE (38.5%). Incidental diagnoses and symptomatic diseases were similar (~50% each), with a 31% requiring hospitalization. Khorana Scores were intermediate and high (77.4%) in this population. The most common risk factors identified in the study included female sex, elevated BMI, hypertension and diabetes co-morbidities, metastatic stage, colorectal and breast cancer sites, and anti-neoplastic therapy administration within the last two months of presentation.

The study highlights several aspects, some of which are controversial, related to TEEs in cancer patients. One of these is sex. Many reports have suggested that TEEs are more common in females (12, 27); others, however, have not confirmed this finding (28–30). In our study, the majority of our subjects who had TEEs (69.0%) were females. Certain comorbidities (cardiovascular, hypertension, diabetes, and obesity) have been shown to considerably increase the risk for TEE development (31). In our study, 47 (27.0%) and 37 (21.3%) of the patients had hypertension and diabetes, respectively. These numbers are not different from the incidence of diabetes and hypertension in the general population in our region (32, 33).
Colorectal cancer was the commonest cancer seen in our study, with 33 patients representing 19% of our patient’s population. This finding is not consistent with many other studies (5, 13, 34) and might indicate a higher risk for TEEs in our colorectal patients, which represents the second commonest solid tumor after breast cancer, seen at our institution(35). Breast cancer represents a low-risk type of malignancy in most risk models, such as Khorana Score (23, 27); however, it was the second most common malignancy (18.4%) with TEEs in our patient population.

We also looked at other reported risk factors that affect the incidence of TEEs in cancer patients. Performance status is one of them. Previous reports have demonstrated that poor performance status is an important risk factor for VTEs in cancer patients (34, 36). In our study, patients with ECOG performance status scores of 2 or more had the highest frequency (47.7%) of TEEs. However, the percentage of patients with ECOG performance status 1 was still relatively high (30.5%). Advanced stage and anti-neoplastic therapy are other important identified risk factors (13, 37, 38). In our study, 71.8% of patients had metastatic disease, 75% were on anti-neoplastic therapy, and 65.5% had metastatic disease and were on anti-neoplastic therapy. Of note, capecitabine and oxaliplatin were the most common agents used medications in our cohort of patients. An epirubicin, oxaliplatin, and capecitabine (EOX) regimen had been implicated, with an increased incidence of TEEs in gastric and esophageal cancer patients receiving pre-operative or peri-operative chemotherapy (39, 40). Most of the data related to capecitabine and oxaliplatin in colorectal cancer were, however, coupled with bevacizumab, which has thromboembolic properties in itself (41, 42). Twenty-four (13.8%) of the TEEs were catheter-related. Catheter-related thrombosis was low but more common than expected. Historically, catheter-related TEEs are more likely to be diagnosed incidentally and to occur in PICC lines than implantable catheters (43, 44). Hospitalization is also an important risk factor for TEEs in general (45), and more so for cancer-associated TEEs (32). This risk factor did represent one-fourth (23%) of all TEEs diagnosed in our study group.

TEEs in cancer patients adversely affect survival whether discovered symptomatically or incidentally through routine imaging (46, 47). In our study, nearly half of the TEE cases presented with incidental VTE. These findings were supported by other studies showing that incidental VTE accounts for half of TEE cases (48, 49). In addition to affecting survival, TEE in cancer patients places a humanistic and economic burden on patients and institutions (50). In our study, around one-third (31%) of our patients had to be admitted for their TEEs.

Several attempts have been made to identify patients at high risk of developing TEEs by developing risk assessment models. The most used model has been the Khorana scoring system (23). Many other risk assessment models have also been established (27, 29, 32). The majority of the patients in our study fell in the intermediate and high-risk score for the Khorana Model, constituting 77.4%. Recently, two trials tested the efficacy of oral anticoagulants in the prevention of venous thromboembolic events in patients with intermediate or high-risk Khorana Scores. In the CASSINI trial, rivaroxaban significantly reduced the number of VTEs and VTE-related deaths during the on-treatment period (50). Similarly, in the AVERT trial,
apixaban resulted in a significantly lower rate of VTE than the placebo in patients with intermediate and high-risk Khorana Scores (51).

Our study has several limitations. First, it is a single institution and a retrospective study. Additionally, the study does not calculate the incidence of TEE in our patients’ population.

Conclusion

Our study confirms the high burden of TEE in cancer patients. It also highlights the risk factors, including advanced cancer stage, cancer site, anti-neoplastic therapy, central venous catheters, and the role of certain chemotherapy agents, in the development of TEEs in cancer patients. It also supports the importance of risk assessment models in identifying cancer patients at risk of TEE, and the need for future studies to establish treatment prevention in those patients with intermediate and high scores.

Abbreviations

TEEs: Thromboembolic events.

VTEs: Venous thromboembolisms

ATEs: Arterial thromboembolisms

ECOG: Eastern Cooperative Oncology Group

BMI: Body mass index

Declarations

Ethics approval and consent to participate:

The study was approved by the institutional review board under the number RAC 2141-138. In view of the retrospective nature of the study, a waiver of consent was obtained from the institutional review board.

Consent for publication:

Not applicable

Availability of data and materials:

All data generated and analyzed during this study are available upon request.

Competing interests:

The authors have no financial or proprietary interests in any material discussed in this article.
**Funding:**

No funds, grants, or other support was received.

**Authors' contributions:**

All authors contributed to the design and collecting data of the study. ME was responsible for the statistics part. SB and FM had the lead in writing and editing the manuscript.

**Acknowledgment:**

None

**References**

1. Varki A. Trousseau's syndrome: multiple definitions and multiple mechanisms. Blood. 2007;110(6):1723-9.
2. Sutherland DE, Weitz IC, Liebman HA. Thromboembolic complications of cancer: epidemiology, pathogenesis, diagnosis, and treatment. Am J Hematol. 2003;72(1):43-52.
3. Levitan N, Dowlati A, Remick SC, Tahsildar HI, Sivinski LD, Beyth R, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore). 1999;78(5):285-91.
4. Lee AY, Levine MN. Venous thromboembolism and cancer: risks and outcomes. Circulation. 2003;107(23 Suppl 1):I17-21.
5. Amer MH. Cancer-associated thrombosis: clinical presentation and survival. Cancer Manag Res. 2013;5:165-78.
6. Oh SY, Kim JH, Lee KW, Bang SM, Hwang JH, Oh D, et al. Venous thromboembolism in patients with pancreatic adenocarcinoma: lower incidence in Asian ethnicity. Thromb Res. 2008;122(4):485-90.
7. Kang MJ, Ryoo BY, Ryu MH, Koo DH, Chang HM, Lee JL, et al. Venous thromboembolism (VTE) in patients with advanced gastric cancer: an Asian experience. Eur J Cancer. 2012;48(4):492-500.
8. Kim JW, Chun EJ, Choi SI, Park DJ, Kim HH, Bang SM, et al. A prospective study on the incidence of postoperative venous thromboembolism in Korean gastric cancer patients: an inquiry into the application of Western guidelines to Asian cancer patients. PLoS One. 2013;8(4):e61968.
9. Huang H, Korn JR, Mallick R, Friedman M, Nichols C, Menzin J. Incidence of venous thromboembolism among chemotherapy-treated patients with lung cancer and its association with mortality: a retrospective database study. J Thromb Thrombolysis. 2012;34(4):446-56.
10. Stricker H. Venous thromboembolism and cancer: pathophysiology and incidence. VASA Zeitschrift fur Gefasskrankheiten. 2014;43(4):239-43.
11. Horsted F, West J, Grainge MJ. Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis. PLoS medicine. 2012;9(7):e1001275.
12. Streiff MB. Association between cancer types, cancer treatments, and venous thromboembolism in medical oncology patients. Clinical advances in hematology & oncology : H&O. 2013;11(6):349-57.
13. Moore RA, Adel N, Riedel E, Bhutani M, Feldman DR, Tabbara NE, et al. High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis. J Clin Oncol. 2011;29(25):3466-73.
14. Qi WX, Lin F, Sun YJ, Tang LN, Shen Z, Yao Y. Risk of venous and arterial thromboembolic events in cancer patients treated with gemcitabine: a systematic review and meta-analysis. Br J Clin Pharmacol. 2013;76(3):338-47.
15. Hernandez RK, Sorensen HT, Pedersen L, Jacobsen J, Lash TL. Tamoxifen treatment and risk of deep venous thrombosis and pulmonary embolism: a Danish population-based cohort study. Cancer. 2009;115(19):4442-9.
16. Choueiri TK, Schutz FA, Je Y, Rosenberg JE, Bellmunt J. Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. J Clin Oncol. 2010;28(13):2280-5.
17. Ranpura V, Hapani S, Chuang J, Wu S. Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials. Acta Oncol. 2010;49(3):287-97.
18. Petrelli F, Cabiddu M, Borgonovo K, Barni S. Risk of venous and arterial thromboembolic events associated with anti-EGFR agents: a meta-analysis of randomized clinical trials. Ann Oncol. 2012;23(7):1672-9.
19. Konigsbrugge O, Pabinger I, Ay C. Risk factors for venous thromboembolism in cancer: novel findings from the Vienna Cancer and Thrombosis Study (CATS). Thromb Res. 2014;133 Suppl 2:S39-43.
20. Lyman GH, Khorana AA, Kuderer NM, Lee AY, Arcelus JJ, Balaban EP, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013;31(17):2189-204.
21. Guyatt GH, Akl EA, Crowther M, Guterman DD, Schuunemann HJ, American College of Chest Physicians Antithrombotic T, et al. Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):7S-47S.
22. Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111(10):4902-7.
23. Ay C, Dunkler D, Marosi C, Chiriac AL, Vormittag R, Simanek R, et al. Prediction of venous thromboembolism in cancer patients. Blood. 2010;116(24):5377-82.
24. Verso M, Agnelli G, Barni S, Gasparini G, LaBianca R. A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score. Intern Emerg Med. 2012;7(3):291-2.
25. Pelzer U, Sinn M, Stieler J, Riess H. [Primary pharmacological prevention of thromboembolic events in ambulatory patients with advanced pancreatic cancer treated with chemotherapy?]. Dtsch Med
26. Pabinger I, van Es N, Heinze G, Posch F, Riedl J, Reitter EM, et al. A clinical prediction model for cancer-associated venous thromboembolism: a development and validation study in two independent prospective cohorts. Lancet Haematol. 2018;5(7):e289-e98.

27. Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer. 2007;110(10):2339-46.

28. Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005;293(6):715-22.

29. Farge D, Bounameaux H, Bauersachs RM, Brenner B. Women, thrombosis, and cancer: A gender-specific analysis. Thromb Res. 2017;151 Suppl 1:S21-S9.

30. Chew HK, Wun T, Harvey D, Zhou H, White RH. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med. 2006;166(4):458-64.

31. Gerotziafas GT, Taher A, Abdel-Razeq H, AboElnazar E, Spyropoulos AC, El Shemmari S, et al. A Predictive Score for Thrombosis Associated with Breast, Colorectal, Lung, or Ovarian Cancer: The Prospective COMPASS-Cancer-Associated Thrombosis Study. Oncologist. 2017;22(10):1222-31.

32. Meo SA. Prevalence and future prediction of type 2 diabetes mellitus in the Kingdom of Saudi Arabia: A systematic review of published studies. J Pak Med Assoc. 2016;66(6):722-5.

33. Yoon SS, Carroll MD, Fryar CD. Hypertension Prevalence and Control Among Adults: United States, 2011-2014. NCHS Data Brief. 2015(220):1-8.

34. Al Diab AI. Cancer-related venous thromboembolism: insight into underestimated risk factors. Hematol Oncol Stem Cell Ther. 2010;3(4):191-5.

35. King Faisal Specialist Hospital and Research Center Cancer Registry Report 2014 [Available from: https://www.kfshrc.edu.sa/store/media/8el.pdf.

36. Pabinger I, Ay C. Risk of venous thromboembolism and primary prophylaxis in cancer. Should all patients receive thromboprophylaxis? Hamostaseologie. 2012;32(2):132-7.

37. Blom JW, Vanderschoot JP, Oostindier MJ, Osanto S, van der Meer FJ, Rosendaal FR. Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study. J Thromb Haemost. 2006;4(3):529-35.

38. Papaxoinis G, Kamosioras K, Germetaki T, Weaver JMJ, Stamatochoulou S, Nasralla M, et al. Predictive factors of thromboembolic complications in patients with esophagagal adenocarcinoma undergoing preoperative chemotherapy. Acta Oncol. 2018;57(6):790-8.

39. Khanna A, Reece-Smith AM, Cunnell M, Madhusudan S, Thomas A, Bowrey DJ, et al. Venous thromboembolism in patients receiving perioperative chemotherapy for esophagagal cancer. Dis Esophagus. 2014;27(3):242-7.

40. Van Cutsem E, Rivera F, Berry S, Kretzschmar A, Michael M, DiBartolomeo M, et al. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol. 2009;20(11):1842-7.
41. Hong YS, Lee J, Kim KP, Lee JL, Park YS, Park JO, et al. Multicenter phase II study of second-line bevacizumab plus doublet combination chemotherapy in patients with metastatic colorectal cancer progressed after upfront bevacizumab plus doublet combination chemotherapy. Invest New Drugs. 2013;31(1):183-91.

42. Yukisawa S, Fujiwara Y, Yamamoto Y, Ueno T, Matsueda K, Kohno A, et al. Upper-extremity deep vein thrombosis related to central venous port systems implanted in cancer patients. Br J Radiol. 2010;83(994):850-3.

43. Saber W, Moua T, Williams EC, Verso M, Agnelli G, Couban S, et al. Risk factors for catheter-related thrombosis (CRT) in cancer patients: a patient-level data (IPD) meta-analysis of clinical trials and prospective studies. J Thromb Haemost. 2011;9(2):312-9.

44. Tagalakis V, Patenaude V, Kahn SR, Suissa S. Incidence of and mortality from venous thromboembolism in a real-world population: the Q-VTE Study Cohort. Am J Med. 2013;126(9):832 e13-21.

45. O’Connell C, Razavi P, Ghaliichi M, Boyle S, Vasan S, Mark L, et al. Unsuspected pulmonary emboli adversely impact survival in patients with cancer undergoing routine staging multi-row detector computed tomography scanning. J Thromb Haemost. 2011;9(2):305-11.

46. Connolly GC, Menapace L, Safadjou S, Francis CW, Khorana AA. Prevalence and clinical significance of incidental and clinically suspected venous thromboembolism in lung cancer patients. Clin Lung Cancer. 2013;14(6):713-8.

47. van Es N, Bleker SM, Di Nisio M. Cancer-associated unsuspected pulmonary embolism. Thromb Res. 2014;133 Suppl 2:S172-8.

48. Dentali F, Ageno W, Becattini C, Galli L, Gianni M, Riva N, et al. Prevalence and clinical history of incidental, asymptomatic pulmonary embolism: a meta-analysis. Thromb Res. 2010;125(6):518-22.

49. Kourlaba G, Relakis J, Mylonas C, Kapaki V, Kontodimas S, Holm MV, et al. The humanistic and economic burden of venous thromboembolism in cancer patients: a systematic review. Blood Coagul Fibrinolysis. 2015;26(1):13-31.

50. Khorana AA, Soff GA, Kakkar AK, Vadhan-Raj S, Riess H, Wun T, et al. Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer. N Engl J Med. 2019;380(8):720-8.

51. Carrier M, Abou-Nassar K, Mallick R, Tagalakis V, Shivakumar S, Schattner A, et al. Apixaban to Prevent Venous Thromboembolism in Patients with Cancer. N Engl J Med. 2019;380(8):711-9.